Research Article
[Retracted] C-Reactive Protein as a Prognostic Biomarker for Gynecologic Cancers: A Meta-Analysis
Table 2
HRs and 95% CIs of patient survival or cancer progression in association with CRP in eligible studies.
| | First author, publication year | Cut-off value (mg/L) | PFS/DFS/RFS/DSS HR (95% CI) | OS HR (95% CI) |
| | Schmid et al. 2007 [36] | 5 | 1.2 (1.1–1.3) | 1.1 (1.05–1.3) | | Six et al. 2008 [33] | 5 | 4.3 (0.9–13.7) | NM | | Hefler et al. 2008 [28] | 10 | 1.81 (1.81–2.74) | 1.81 (1.81–2.74) | | Stephan et al. 2011 [23] | 5 | 1.2 (1.1–1.4) | 1.4 (1.2–1.8) | | Dobrzycka et al. 2013 [27] | 11.19 | 0.84 (0.72–2.84) | 1.87 (0.58–2.87) | | Nakamura et al. 2015 [21] | 7 | NM | 1.858 (0.644–5.357) | | Zhang et al. 2015 [29] | 10 | 1.49 (1.096–2.027) | 1.435 (1.023–2.013) | | Lu et al. 2015 [31] | 8 | NM | 2.18 (1.3–3.67) | | Li et al. 2015 [34] | 8.2 | 7.24 (3.27–16.02) | NM | | Xiao et al. 2015 [26] | 10 | 1.88 (1.32–2.68) | 1.95 (1.31–2.88) | | Bodner–Adler et al. 2016 [19] | 5 | NM | 1.238 (1.064–1.441) | | Liu et al. 2017 [32] | 10 | NM | 1.005 (1.001–1.009) | | He et al. 2018 [25] | 10 | NM | 3.03 (1.34–6.82) | | Wang et al. 2019 [24] | 3.135 | 1.423 (0.866–2.338) | 2.081 (1.096–3.953) | | Wang et al. 2020 [20] | 5 | NM | 2.208 (1.265–3.251) | | An et al. 2020 [22] | NM | 1.32 (0.49–3.14) | 1.25 (0.84–1.81) | | Terlikowska et al. 2020 [35] | NM | NM | 1.22 (1.01–1.43) | | Komura et al. 2020 [30] | 7.6 | 1.96 (1.1–3.57) | NM | | Njoku et al. 2021 [37] | 5.5 | 1.13 (0.58–2.20) | 1.68 (1.00–2.81) |
|
|
Abbreviations: DFS: disease-free survival; DSS: disease-specific survival; HR: HR (high vs. low); NM: not mentioned; OS: overall survival; PFS: progress-free survival; RFS: recurrence-free survival.
|
